Table 3 Association between clinical features and SCP/UCP classification in patients with metastatic NSCLC. Analysis was performed in 84 patients undergoing NGS analysis in plasma according to clinical practice. SCP stable chromosomal profile, UCP unstable chromosomal profile.
Characteristic | SCP, N = 671 | UCP, N = 171 | p-value2 |
|---|---|---|---|
Age—Median (Q1, Q3) | 65 (58,72) | 66 (61,71) | 0.8 |
Sex | > 0.9 | ||
Male | 38 (57%) | 10 (59%) | |
Female | 29 (43%) | 7 (41%) | |
Smoking status | 0.4 | ||
Never | 23 (34%) | 3 (18%) | |
Actual | 15 (22%) | 4 (24%) | |
Former | 29 (43%) | 10 (59%) | |
Number of metastatic sites | 0.009 | ||
< 3 | 55 (82%) | 8 (47%) | |
≥ 3 | 12 (18%) | 9 (53%) | |
Liver mets | 0.010 | ||
Absent | 59 (88%) | 10 (59%) | |
Present | 8 (12%) | 7 (41%) | |
Bone mets | 0.3 | ||
Absent | 42 (63%) | 8 (47%) | |
Present | 25 (37%) | 9 (53%) | |
Brain mets | 0.2 | ||
Absent | 57 (85%) | 12 (71%) | |
Present | 10 (15%) | 5 (29%) | |
Extrathoracic mets | 0.095 | ||
Absent | 44 (66%) | 7 (41%) | |
Present | 23 (34%) | 10 (59%) | |
Histology | 0.2 | ||
Adenocarcinoma | 55 (82%) | 11 (65%) | |
Squamous carcinoma | 8 (12%) | 3 (18%) | |
Others | 4 (6.0%) | 3 (18%) | |
PD-L1 class | 0.7 | ||
< 1% | 26 (46%) | 9 (60%) | |
1–49% | 14 (25%) | 3 (20%) | |
> 50% | 17 (30%) | 3 (20%) | |
Unknown | 10 | 2 | |
PD-L1 positivity | 0.6 | ||
< 1% | 30 (53%) | 6 (40%) | |
> 1% | 27 (47%) | 9 (60%) | |
Unknown | 10 | 2 | |
Known driver mutations | 0.084 | ||
Absent | 34 (54%) | 12 (80%) | |
Present | 29 (46%) | 3 (20%) | |
Unknown | 4 | 2 | |
